Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease
Terminated
NHS Greater Glasgow and Clyde
Phase 2
2005-03-01
The principal research objectives are to demonstrate cardioselective beta-blockade using
bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality
of life in patients with heart failure and coexistent moderate or severe chronic obstructive
pulmonary disease with or without significant reversibility. Patients will be followed up for
4 months during which bisoprolol will be up-titrated to the maximum clinically tolerated
dose. Health status will be assessed using a generic and two disease specific questionnaires,
and pulmonary function by spirometry, body box plethysmography, and cardiopulmonary exercise
testing.
Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition
Completed
IPCA Laboratories Ltd.
Phase 1
2012-08-01
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single
dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence
between Test Product and the corresponding Reference Product under fasting condition in
normal, healthy, adult human subjects.
Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition
Completed
IPCA Laboratories Ltd.
Phase 1
2012-08-01
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single
dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence
between Test Product and the corresponding Reference Product under fed condition in normal,
healthy, adult human subjects.
Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor
Unknown status
Alphacait, LLC
Phase 2
2017-01-01
This is a single-center, open-label, single-arm, non-randomized study designed to evaluate
PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR)
and biomarkers of cancer therapy based on Alphacait screening system in subjects with
advanced malignant tumor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
